January 9, 2017

Johnson and Johnson worldwide chairman, pharmaceuticals, Joaquin  Duato will be the next board chairman of PhRMA. 

January 6, 2017

The number of drugs the FDA approved last year, 22, is less than half of the 45 approved in 2015 and lower than the average of the last 10 years of approvals, which is 29. 

January 6, 2017
This is the fifth approved indication for Lucentis. 
January 6, 2017

U.S. District Court Judge Sue Robinson on Thursday issued an injunction on the sale of Praluent, a PCSK9 inhibitor from Sanofi and Regeneron. Amgen, maker of another PCSK9 inhibitor Repatha, filed the request for the injunction in 2016.

January 5, 2017

FHC's new chief commercial officer will be responsible for all sales and marketing activities, with the goal of coordinating prelaunch, launch and sales and marketing activities.

January 4, 2017

Dr. Jay Markowitz will work with other scientific and development leaders to evaluate the company’s portfolio evaluation and decision making while assessing external opportunities. 

January 4, 2017

The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 

January 3, 2017
Forbes is reporting that the Food and Drug Administration’s approval of 22 new drugs in 2016 (down from 51 in 2015) could have big implications for the future of innovation in the pharmaceutical space. The report notes that research spending is growing, but there are practical difficulties to translate innovation into products as R&D returns decline  — and the report suggests overcoming that difficulty could mean rethinking a lot. (Forbes)
 
December 27, 2016

Spinraza treats SMA, a rare and often fatal genetic disease affecting muscle strength and movement.

December 27, 2016

Novo Nordisk accused of issuing marketing materials asking patients and doctors to switch from Sanofi’s Lantus and Toujeo drugs to Tresiba, because the Sanofi drugs will be “blocked” by CVS Caremark in January.

December 22, 2016

Dexcom’s G5 Mobile allows for testing for diabetes treatment decisions in people 2 years of age and older with diabetes.

December 21, 2016

Systemic inflammatory conditions combined affect more than 2 million Americans.

December 21, 2016

Walgreens has expanded the availability of prescription-free naloxone to 33 states and the District of Columbia.

December 16, 2016

Removal based on the outcomes of EAGLES, the largest smoking cessation clinical trial in patients without and with a history of psychiatric disorder.

December 15, 2016

The drug’s availability comes a year after the Food and Drug Administration approved it as a follow-on biologic to Lantus, another U-100 long-acting insulin. It has an amino acid sequence identical to that of Lantus. 

December 15, 2016

Expanding by 13 the list of vaccinations that can be administered to patients is part of the province's new strategy, Immunization 2020, which focuses on improving access to immunizations.

December 15, 2016

Walgreens ranks the top markets and states for flu activity in the U.S. It's the third year for Walgreens' Flu Index, and this year will include Puerto Rico for the first time.

December 14, 2016

Pfizer's Eucrisa came into its portfolio in May with the company’s acquisition of Anacor Pharmaceuticals, and Pfizer projects that it could bring in $2 billion or more in annual sales. 

December 13, 2016

The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken.

December 13, 2016

Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 

December 9, 2016
The focus of the initiative, which will see Lilly making an upfront payment of $30 million to AstraZeneca, is an antibody called MEDI1814, which can potentially slow the progression of the illness and is currently in Phase 1 trials. 
December 9, 2016

London Drugs is hoping to beat Shoppers Drug Mart to market in terms of dispensing medical marijuana, Canada's Tri-City News reported Thursday. “We’ll be as fast as the laws allow," London Drugs VP John Tse told the Candadian daily, "but it could happen overnight, we’re that ready." London Drug pharmacists are already reviewing potential drug-drug interactions. "We're interested from the perspective of how does it affect other medication the patient might be on and other health conditions they might have,” Tse said. “As a pharmacy we want it all documented properly so that we can advise patients and other health care professionals.” (Tri-City News)

December 8, 2016

In addition to returning the rights to Belbuca to BioDelivery Sciences International, Endo will be eliminating its 375-member pain sales field force in an effort to refocus its U.S. branded strategy on specialty, including its Xiaflex. 

December 8, 2016

The company told USA Today the cuts would take effect Feb. 10, with its Fairfax, Delaware headquarters seeing about 120 of the expected cuts, with other impacted roles spanning those that are field-based in both sales and non-sales.